Healionics Awarded SBIR Contract from DOD to Develop Biointegrated Synthetic Vascular Graft

Healionics Corporation has been awarded a $150,000 Small Business Innovation Research (SBIR) contract from the Department of Defense (DOD) to demonstrate feasibility for an improved vascular graft design. Andrew Marshall, PhD, Healionics’ Chief Technology Officer, is the Principal Investigator for this research project.

Titled, “Biointegrated Synthetic Grafts for Vascular Reconstruction,” the contract provides sixmonth funding to show proof of concept for a new approach to prevent clotting failures of prosthetic arterial bypass grafts.

The current standard approach to repairing damaged or clotted arteries is to bypass the damaged region with a vein harvested from elsewhere in the body, but many patients do not have healthy suitable veins available. An improved synthetic blood vessel would benefit these patients.

About Healionics Corporation
Healionics develops and manufactures STAR Biomaterials for implanted medical devices. The precisely controlled pore structure of the innovative STAR technology induces a favorable integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance and longevity.